Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous alpha-PNE switchable CAR T cells CLBR001

A preparation of autologous T lymphocytes that has been genetically engineered to express a switchable, alpha-peptide neo-epitope (PNE) chimeric antigen receptor (CAR) with a binding domain that can recognize a 14 aa peptide epitope, or PNE, of an antigen-specific adapter molecule, with potential immunomodulating and antineoplastic activities. Upon administration, autologous alpha-PNE switchable CAR T (sCART) cells CLBR001 remain inactivated. Upon administration of an antigen-specific adapter molecule, the binding domain of CLBR001 binds to the PNE of the adapter molecule, and CLBR001 is activated. This induces selective toxicity in and causes lysis of tumor cells expressing the specific antigen.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous alpha-peptide neo-epitope CAR-T cells CLBR001
autologous alpha-PNE CAR T cells CLBR001
autologous alpha-PNE CAR T lymphocytes CLBR001
autologous alpha-PNE sCAR-T cells CLBR001
Code name:CLBR 001
CLBR-001
CLBR001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search